Regentis Biomaterials Ltd. (RGNT)
| Market Cap | 20.35M |
| Revenue (ttm) | n/a |
| Net Income | -333,000 |
| EPS | -2.05 |
| Shares Out | 5.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,263 |
| Open | 4.380 |
| Previous Close | 4.390 |
| Day's Range | 3.930 - 4.635 |
| 52-Week Range | 3.930 - 8.350 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About RGNT
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions in the United States. The company offers orthopedic treatments using Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. It offers Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylat... [Read more]
News
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S. Ori Gon brings substantial...
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs GelrinC is set to transform cartilage repair market wit...
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint function This...
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint New peer-reviewed data published in the scientif...
Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeons, resulting in a 10-minute procedure Robust IP portfolio includes 35 issued patents to date w...
U.S. IPO Weekly Recap: December Kicks Off With 3 Notable Launches In A Week With 7 SPACs
The US IPO market entered the final stretch of the year with a few small listings, a wave of SPACs, and three notable deal launches on the calendar for the week ahead. With markets recovering from a r...
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative ...
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative ...
Israeli hydrogel implant developer Regentis Biomaterials files and sets terms for a $10 million US IPO
Regentis Biomaterials, an Israeli regenerative medicine company developing orthopedic hydrogel implants, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering.
Regentis Biomaterials IPO Registration Document (F-1)
Regentis Biomaterials has filed to go public with an IPO on the NASDAQ.